Metabolic Dysfunction-Associated Steatotic Liver Disease
Conditions
Keywords
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), FAST Score, Metabolic Features
Brief summary
The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt. Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score. Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.
Interventions
RADIATIONTransient Elastography
participants will be subjected to anthropometric measurements, laboratory investigations (complete blood count, liver and kidney functions, lipid profile, virology tests, fasting insulin, fasting sugar, 2 hour postprandial sugar, HbA1c, and HOMA-IR), radiological examination (abdominal ultrasound, Fibroscan). the NAFLD fibrosis score, APRI, FIB-4 score, and FAST score will be calculated.
Sponsors
Tanta University
Study design
Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography
Exclusion criteria
* Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women. * Patients with positive hepatitis B or C virus markers. * Patients with autoimmune hepatitis. * Patients with any other metabolic liver disease. * Patients with hepatic focal lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| impact of metabolic features on FAST score | through study completion, an average of 6 months | Calculating the FAST score by combining AST (IU/L) with LSM (kPa) and CAP (dB/m2) measured by Fibroscan for all MASLD patients. Evaluation of which metabolic features (DM, HTN, obesity, dyslipidemia) would be associated with a higher FAST score indicating having steatohepatitis with significant inflammatory activity and fibrosis. |
Countries
Egypt
Contacts
Primary ContactRania M Elkafoury, MD
Backup ContactAmal M Dwidar
Outcome results
None listed